-
Clinical Trial
-
Korean J Obstet Gynecol. 2012;55(3):143-147. Published online March 1, 2012.
DOI: https://doi.org/10.5468/KJOG.2012.55.3.143
- Pharmacotherapy for premenstrual dysphoric disorder: A meta-analysis of phase 3 trials.
-
Sun Kyoung Yum, Min Ji Ryu, Nayoon Park, Seongmin Kim, Kyong Wook Yi, Hyun Tae Park, Jung Ho Shin, Jun Young Hur, Sun Haeng Kim, Tak Kim
-
Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea. tkim@kumc.or.kr
- Abstract
- Premenstrual dysphoric disorder (PMDD) is a common condition that temporarily, but repetitively affects patient's global function. Patients and physicians alike are often uncertain whether prescription medication for PMDD is sufficiently effective. The primary objective of this analysis is signal detection in efficacy of pharmacological treatments in PMDD. Secondary objective is to review which symptoms are likely to respond to which medications. The review included otherwise healthy women with clinician confirmed diagnosis of PMDD who participated in phase 3 clinical trials for the treatment of PMDD. Twelve pair-wise comparisons of drug and placebo for 2,420 patients with PMDD were performed. Oral contraceptives and selective serotonin receptor inhibitor were effective in alleviating symptoms of PMDD compared to placebo. Both Intermittent and continuous administration were more effective than placebo. This meta-analysis provides a signal that pharmacological treatment of PMDD is effective.
Keywords :Premenstrual syndrome;Drug therapy;Meta-analysis;Clinical trial, phase 3
